Pharma Giants Race to Unlock New Cardiology Blockbuster via Lp(a) Targeting

Major pharmaceutical players are pivoting toward a specialized form of cholesterol, lipoprotein(a) or Lp(a), in a bid to create the next generation of cardiovascular blockbusters. Novartis, Amgen, and Eli Lilly are currently in late-stage clinical trials to determine if slashing these levels can significantly reduce the incidence of heart attacks and strokes. Unlike traditional LDL cholesterol, Lp(a) levels are almost entirely determined by genetics, meaning diet and exercise are largely ineffective. This creates a significant unmet medical need, as approximately one in five people worldwide suffer from elevated levels. Lp(a) is considered particularly dangerous because it simultaneously clogs arteries and promotes the formation of blood clots. Novartis, Amgen, and Lilly have already demonstrated that their respective candidates—pelacarsen, olpasiran, and lepodisiran—can reduce Lp(a) levels by more than 80%. However, the industry is now waiting for clinical proof that these reductions translate into tangible patient benefits. If successful, consensus estimates from pharmaceutical intelligence firm Evaluate suggest the market for these therapies could reach $5.6 billion in annual sales by 2032. Novartis is expected to release results from its Phase 3 Horizon trial around the middle of the year. The readout was previously delayed by one year because participants did not experience cardiac events as quickly as anticipated, a trend the company attributes to the effective management of other risk factors among the trial group. The outcome of these trials will determine if Lp(a) becomes a viable new therapeutic class. Analysts note that historical precedents, such as the failure of HDL-raising drugs, suggest that lowering a biomarker does not always guarantee a reduction in clinical events.